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Objectives The study sought to assess the impact of pregnancy on the rate of aortic growth as well as on short- and long-
term clinical outcomes in women with Marfan syndrome.
Background There is a paucity of data on peripartum and long-term clinical outcomes in women with Marfan syndrome who
are followed prospectively during pregnancy.
Methods Echocardiographic, demographic, and surgical data review of all adult females with a confirmed diagnosis of
Marfan syndrome was performed.
Results Of the 98 women identified, 69 (72%) experienced a total of 199 pregnancies resulting in 170 (86%) live births.
The median number of pregnancies per women was 3 (interquartile range: 1 to 12). Obstetrical complications
occurred in 17 (10%) and adverse fetal outcomes in 22 (13%). No woman experienced aortic dissection or re-
quired cardiac surgery during pregnancy. Aortic growth rate increased during pregnancy and did not return to
baseline following pregnancy completion. Despite the lack of catastrophic peripartum complications, the preva-
lence of both aortic dissection and elective aortic surgery during long-term follow-up was higher in those women
who had a prior pregnancy. Risk factors for adverse cardiac outcome included greater aortic diameter, greater
rate of aortic growth during pregnancy, increased number of pregnancies, lack of beta-blocker use during preg-
nancy, and lack of prospective pregnancy follow-up.
Conclusions There is a low incidence of aortic complications during pregnancy in women with Marfan syndrome and an aortic
diameter 4.5 cm. However, pregnancy does increase the risk of aortic complications in the long-term in this
group of patients. (J Am Coll Cardiol 2012;60:224–9) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.051d
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pMarfan syndrome (MFS) is an autosomal dominant connec-
tive tissue disorder caused by a mutation in the FBN-1 gene
ncoding for the glycoprotein, fibrillin (1). While MFS is
ssociated with diverse clinical manifestations in multiple
rgan systems, it is the cardiovascular complications of aortic
ilation and dissection that account for the morbidity and
ortality associated with the disease (2). Risk factors for
dverse aortic outcomes, namely the need for aortic surgery,
ortic insufficiency, and aortic dissection, have been identified
nd include greater aortic size (2), obesity (3), family history of
aortic dissection (2), and older age (2). The impact of gender
n risk remains controversial with some studies noting female
ender, and others, male gender, as a risk factor for aortic
issection.
From the Division of Cardiology, Department of Pediatrics, Primary Children’s
Medical Center, University of Utah, Salt Lake City, Utah. All authors have reported
that they have no relationships relevant to the contents of this paper to disclose.Manuscript received July 21, 2011; revised manuscript received February 8, 2012,
accepted March 6, 2012.Numerous case reports and 8 retrospective studies have
documented aortic dissection during, or immediately follow-
ing, pregnancy in women with MFS (4–9). In the majority of
these women the diagnosis of MFS was unknown at the
time of pregnancy (4–9). As a result of this retrospective
ata, which are inherently subject to selection bias, women
ithMFS in the United States are counseled to avoid pregnancy,
r alternatively, undergo surgical ascending aortic replacement
rior to conception, if the aorta measures 4 cm (10).
See page 230
Perhaps as a result, there is very little prospective data
assessing the impact of pregnancy on aortic growth and
clinical outcome in women with MFS. We sought to
assess the impact of pregnancy on the rate of aortic
growth as well as on short- and long-term clinical
outcomes in a group of women with MFS followed by a
cardiologist prospectively throughout pregnancy.
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An institutional review board–approved retrospective review
of clinical records on all patients seen in a tertiary cardiology
subspecialty aortopathy clinic over the past 10 years was
performed. The aortopathy clinic is a regional referral center
for a 6-state region. Obstetrical and cardiac data are stored
within a statewide electronic medical record system.
Detailed echocardiographic and demographic data on all
patients satisfying inclusion criteria were obtained and
included for review. For inclusion into the study the patient
needed to fulfill Ghent criteria for a diagnosis of MFS either
with or without confirmatory genetic testing (11), be a
female of 18 years of age having attained final height as
evidenced by no change in height over the year prior to
initiation of data collection, and have had a clinic visit
within the past 18 months or documentation of death.
Women with a documented TGFBRI or TGFBRII muta-
tion, or clinical features suggestive of such in the absence of
genetic testing, including arterial tortuosity, suggestive facial
features, or abnormal uvula (12), were excluded from data
collection.
Subjects were categorized as those having had, and those
not having had, a previously documented pregnancy irre-
spective of outcome. Women with a prior pregnancy were
further subdivided into those receiving, and those not
receiving, prospective cardiac care during pregnancy. Women
followed prospectively with a confirmed diagnosis of MFS
prior to pregnancy, underwent echocardiography at a min-
imum of once within the 12 months prior to pregnancy, at
12 to 16 weeks’ gestation, 24 to 26 weeks’ gestation, 35 to
39 weeks’ gestation, 4 to 16 weeks postpartum, and then
annually as is our clinical protocol. Additional echocardio-
grams were performed if there was clinical cause for con-
cern. Nulliparous females and females not receiving pro-
spective cardiac care during pregnancy had a minimum of
annual echocardiograms from the time of diagnosis until last
follow-up.
Data on 2 clinical outcomes was recorded: 1) a composite
adverse outcome, defined as death, aortic dissection, severe
symptomatic aortic insufficiency, or need for urgent surgery;
and 2) the need for elective aortic surgery during the period
of clinical follow-up.
For all 3 patient groups: 1) pregnancy followed prospec-
tively; 2) pregnancy not followed prospectively; 3) no prior
pregnancy, the following data were recorded: age at diag-
nosis, type and duration of medical therapy, presence or
absence of a family history of MFS, and duration of
follow-up after first pregnancy, or in the case of nulliparous
controls, after age 18 years.
Cardiac and obstetric data collection varied dependent on
patient group but in all cases was acquired prospectively and
documented in the patient’s obstetrical or cardiac medical
records. For pregnant females receiving prospective cardiac
care, cardiac data recorded included age, blood pressure,
weight, height, body surface area, presence or absence ofcardiac symptoms, aortic root diam-
eter, presence or absence of aortic
dissection, and degree of aortic in-
sufficiency at: 1) time of initial visit at
age 18 years with final height at-
tained; 2) subsequent visits prior to pregnancy; 3) all visits during
pregnancy as defined previously; 4) visit 4 to 12weeks postpartum;
5) annual visits subsequent to a pregnancy; and 6) last follow-up
visit prior to surgery or death.
For pregnant females not receiving prospective cardiac
care, recorded data included age at each pregnancy, current
age, blood pressure at peripartum visits, most recent blood
pressure, current weight, height, body surface area, presence
or absence of aortic dissection, or need for elective aortic
replacement. Aortic diameter prior to any pregnancy (when
available) and most recent aortic diameter prior to surgery or
adverse outcome were obtained.
For all females with a prior pregnancy, cardiac and
obstetrical records were reviewed to determine the interval
between pregnancies, the presence of maternal pregnancy
complications including fetal loss, ectopic pregnancy, ges-
tational diabetes, pregnancy-induced hypertension, pre-
term labor 37 weeks, and the need and indication for
cesarean section. Neonatal data including gestational age at
delivery, birth weight, and presence or absence of a subse-
quent diagnosis of Marfan syndrome in the offspring was
recorded.
Nulliparous controls. A control group of adult women
who had not had a prior pregnancy was identified. Demo-
graphic data recorded included age, blood pressure, weight,
height, body surface area, presence or absence of cardiac
symptoms, aortic root diameter and degree of aortic insuf-
ficiency at initial adult visit as defined previously, and at last
follow-up visit prior to surgery or death.
Echocardiographic analyses. Echocardiographic review
included documentation of the sinus of Valsalva diameter in
systole measured off-line from parasternal long-axis 2-D
images using inner-edge-to-inner-edge technique (13).
Aortic insufficiency was noted to be absent, trivial, mild,
moderate, or severe based on aortic insufficiency jet to
annulus ratio. Aortic diameters were expressed as absolute
values, as indexed values based on age and body surface area,
and as z-scores based on normative data for body surface
area where appropriate. Indexed values were calculated in
order to control for the normal increase in aortic size with
age, and for increase in somatic size over time when in the
nonpregnant state (14). Changes in absolute aortic diameter
over time were calculated as the change in absolute aortic
diameter divided by days between echocardiographic studies
and expressed as millimeters per month.
Clinical practice. All women followed prospectively were
followed by cardiology and maternal fetal medicine
throughout the pregnancy. Women were seen on a monthly
basis by cardiology with echocardiographic frequency as
noted previously. Metoprolol 25 mg twice daily (bid) was
Abbreviations
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Pregnancy in Marfan Syndrome July 17, 2012:224–9dilation to all women irrespective of baseline blood pressure.
Medication was uptitrated if required to maintain a systolic
blood pressure 120 mm Hg. Hypertension was defined as
a systolic or diastolic blood pressure 135 mm Hg or 85
mm Hg, respectively. All women with elevated blood
pressure refractory to medical management were placed on
in-hospital bed rest. All women with significant aortic
dilation, defined as5.0-mm increase inmaximal aortic diameter
from baseline with attainment of an absolute aortic diameter
4 cm, were delivered if fetal viability was expected.
Cesarean section or a passive second stage of labor with
regional anesthesia (absence of pushing, with forceps or
vacuum extraction) at term (37 weeks) was otherwise
recommended. Induction of labor was avoided unless there
was obstetrical reason to proceed with such. Peripartum
recommendations included hospital admission until a min-
imum of 72 h post-delivery and an echocardiogram prior to
discharge. All women were seen in a subspecialty cardiology
clinic within 2 months following delivery. Women receiving
metoprolol were maintained on therapy for 3 months
following delivery with the dose adjusted to maintain a
blood pressure of 120 mm Hg without symptoms of
hypotension.
Statistical analysis. Analysis was conducted using Stata
10.0 (Stata Corp., College Station, Texas). Continuous data
are expressed as mean SD or median (interquartile range)
s appropriate and categorical data were tabulated. A
-sided p value 0.05 was considered statistically signifi-
ant. Demographic and echocardiographic data for women
ith prior pregnancy versus nulliparous females was com-
ared using chi-square test for dichotomous or categorical
ariables and t test or rank sum test for continuous variables
epending on their normality. Echocardiographic measure-
ents used for these initial analyses included aortic root
iameter at initial echocardiogram in adulthood and aortic
oot diameter at last echocardiogram during follow-up or
rior to surgical intervention or death. The primary out-
ome measures were measured as dichotomous variables and
ere compared for the 2 groups using chi-square analysis.
he association of clinical factors with adverse cardiac
utcome and need for elective surgery was analyzed by
ogistic regression. Factors that had a p value 0.2 were
ncluded in a multiple logistic regression model to deter-
ine the adjusted odds ratio. Variables were retained if they
hanged the point estimate by more than 10%. Echocardio-
raphic and demographic variables associated with maternal
r fetal pregnancy complications were also examined using
hi-square, t, or rank sum test as appropriate.
For the women followed prospectively during pregnancy,
ifferences in aortic growth rates were calculated for the
ollowing time periods: 1) baseline: last aortic root measure-
ent prior to pregnancy less initial adult measurement
ivided by the intervening time interval; 2) pregnancy: last
ecorded aortic root measurement in pregnancy or immedi-
tely post-pregnancy (whichever was larger) less initial
regnancy measurement divided by the intervening timeinterval; 3) post-pregnancy: last recorded aortic root mea-
surement at follow-up or prior to surgery or dissection less
initial postpartum measurement divided by the intervening
time interval.
Aortic growth rates for the 3 time periods were analyzed
for equality of variances and then compared using both a
paired t test with unequal variance and a Pearson correlation
oefficient. Aortic growth rates between women followed
rospectively during pregnancy and nulliparous women
ere compared.
esults
ntire pregnancy cohort. Of the 98 women who were
ollowed in the aortopathy clinic, and whom satisfied the
nclusion criteria outlined previously, 69 (72%) experienced
total of 199 pregnancies resulting in 170 (86%) live births,
6 (13%) spontaneous abortions, and 2 ectopic pregnancies.
here were no elective terminations, which is reflective of
he low overall pregnancy termination rate of the state. The
regnancy cohort experienced between 1 and 12 pregnancies
median 3). The remaining 29 women did not have a prior
regnancy and served as the nulliparous control group. No
oman was lost to follow-up care.
Of those women with a prior pregnancy, 35 (51%) were
ollowed prospectively during the pregnancy with routine
chocardiography whereas 34 (49%) women had prior
regnancies without routine peripartum cardiac evaluation.
f those not routinely followed by a cardiologist during
regnancy, 30 (88%) did not receive such care as the
iagnosis of maternal Marfan syndrome was unsuspected at
he time of pregnancy.
Of the 170 pregnancies resulting in live births, obstetrical
omplications occurred in 17 (10%) including pregnancy-
nduced hypertension in 9 (5%), hyperemesis in 1 (1%),
nd premature labor in 7 (4%). Cesarean section was
erformed in 20 (12%). In all cases, this was a planned
rocedure for concern over maternal health secondary to
ortic dilation4 cm, or repeat procedure. All other women
eceiving routine peripartum cardiac care underwent a
aginal delivery with vacuum or forceps extraction. There
as no relationship between the presence of obstetrical
omplications and maternal age (21.5 vs. 25.4 years, p 
.8), interval between pregnancies (15.0 vs. 15.5 months,
 0.5), or pre-pregnancy aortic diameter (36.9 vs. 35.4
mm, p  0.33). The frequency of pregnancy complications
did not differ from that of the general population of the state
(15). Neonatal outcomes included small for gestational age
in 9 (5%), prematurity 37 weeks in 10 (6%), neonatal
death secondary to complications of extreme prematurity in
2 (1%), and congenital cystadenomatoid malformation in 1
(1%). Adverse fetal outcome was associated with a higher
rate of beta-blocker usage (28% vs. 7%, p  0.002),
although women with a larger aorta during pregnancy were
more likely to be receiving beta-blocker medicine (p 
0.0004). Maternal age at delivery and interval between
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Of the 167 offspring surviving the neonatal period, 125
(75%) underwent clinical and echocardiographic evaluation
for MFS. A confirmatory diagnosis was made in 88 (70%)
all of whom had cardiac involvement.
Within the entire cohort of women experiencing a
pregnancy there were no acute aortic dissections. Two
women, both of whom were known to have MFS but were
not receiving routine cardiac care throughout pregnancy,
developed symptomatic carotid artery dissections; 1 pre-
sented with symptoms of a transient ischemic attack in the
third trimester, and the other an enlarging pulsatile neck
mass after routine vaginal delivery without assistance. No
woman required intrapartum cardiovascular surgery or preg-
nancy termination. One patient with a 49-mm aorta and
mild aortic insufficiency entering into the pregnancy devel-
oped New York Heart Association functional class II
symptoms in the face of severe aortic insufficiency at 38
weeks’ gestation and went on to have aortic root replace-
ment at 6 months postpartum. Of the 10 pregnancies
complicated by premature delivery, early delivery occurred
as a result of pre-term labor in 6, pregnancy-induced
hypertension in 2, and progressive aortic dilation (5 mm
from baseline) with an absolute aortic diameter of 4.0 cm
in 2. Both of the latter 2 women were delivered at 36 weeks’
gestation.
Women followed prospectively throughout pregnancy.
Complete serial echocardiography with a minimum of 3
pre-pregnancy echocardiograms, 3 intrapartum echocardio-
grams, and 3 post-partum echocardiograms was available for
55 pregnancies in 35 women. Three women each experi-
enced 1 pregnancy following prior elective ascending aortic
replacement and were thus excluded from analyses assessing
Figure 1 Graph of Change in Aortic Growth
Rate Pre-, During, and Post-Pregnancy
Box and whiskers plot graph depicting median aortic growth rate prior to preg-
nancy, during pregnancy and following pregnancy. Shaded box represents the
interquartile range (25% to 75%), and the line in the middle of the box, the
median. The dots represent outliers and the lines that extend from the box are
the maximum and minimum values excluding outliers.iaortic growth rate. Two of the 3 had a valve-sparing
operation while the other had a composite graft with a
mechanical valve. Pregnancy was complicated by progressive
neoaortic insufficiency from trivial to moderate in both
women with valve-sparing procedures.
Excluding the patients with prior aortic surgery, baseline
aortic root diameter within the year prior to pregnancy was
36.1  4.4 mm with 14 (27%) of the pregnancies entered
into with an aortic root diameter of 4.0 cm. Aortic
diameter increased by 3 mm (interquartile range: 0 to 7 mm)
during the course of the pregnancy resulting in an aortic
root diameter of 39.0  6.0 mm at the time of delivery.
ortic growth rate increased significantly during the intra-
artum period and then fell following delivery, albeit re-
aining significantly above the baseline rate (Fig. 1).
regnancy versus nulliparous cohort. As noted in Table 1,
omen with and without a prior pregnancy were well
atched with respect to initial age, body size, and aortic
ize. Women who were not pregnant, however, were more
ikely to be compliant with recommendations for medical
herapy to prevent aortic dilation. At the time of last
ollow-up, women who had a prior pregnancy had a
ignificantly greater aortic diameter (Table 1).
Despite the lack of catastrophic peripartum complica-
ions, the prevalence of both adverse outcome and elective
ortic surgery during long-term follow-up was higher in
hose women who had a prior pregnancy (Table 2). This
nding is in keeping with the higher rate of aortic growth
ocumented during pregnancy compared with each wom-
n’s prior baseline aortic growth rate (Fig. 1).
actors associated with long-term adverse outcome in
regnant women. Factors associated with long-term ad-
erse cardiovascular outcome on univariate analysis within
he entire cohort of patients with prior pregnancy included
reater absolute and indexed aortic size at onset of preg-
ancy, initial pregnancy aortic diameter 4 cm, greater rate
f aortic growth, increased number of pregnancies, lack of
eta-blocker use during pregnancy, and lack of prospective
regnancy follow-up (Table 3). On multivariate analysis,
Demographic VariablesTable 1 Demographic Variables
Variable Pregnant Nulliparous p Value
Baseline age, yrs 24.9 4.7 21.9 7.3 0.07
Baseline aorta, mm 35 (28–51) 36 (26–46) 0.67
Baseline aorta, z 2.6 1.9 3.1 1.7 0.26
Baseline body surface area 1.8 (1.2–2.5) 1.7 (1.2–2.1) 0.16
Family history of Marfan syndrome 56.9% 58.1% 1.00
Medications 38.5% 70.9% 0.004
Follow-up duration, yrs 5.6 3.8 7.7 5.7 0.08
Follow-up aorta, mm 43 (26–90) 37 (25–60) 0.002
Follow-up aorta, z-score 5.2 5.1 3.2 1.8 0.04
Follow-up body surface area 1.9 (1.5–2.6) 1.8 (1.5–2.7) 0.18
Values are mean  SD, median (interquartile range), or %.nitial aortic diameter and rate of change in aortic diameter
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term adverse cardiovascular outcome (Table 4).
Discussion
The data on women with MFS receiving cardiac care during
pregnancy is extremely limited. In the 2 studies to date, no
woman under the care of a cardiologist experienced dissec-
tion of the ascending aorta (15,16). These authors con-
cluded that pregnancy was safe and did not typically impose
a deleterious health impact in unoperated women with MFS
with initial aortic diameters of 45 mm (16). Our study
confirms the findings of the 2 prior prospective studies in
that no woman with a known diagnosis of MFS, who was
under the care of a cardiologist, experienced acute aortic
dissection during the 199 pregnancies followed. While there
are obvious potential risks associated with pregnancy in
these women, these risks may be minimized by timely
diagnosis prior to conception, tight blood pressure control,
use of beta-blockade despite normotension, close echocar-
diographic surveillance, and delivery strategies aimed at
reducing aortic wall stress.
Despite the absence of catastrophic peripartum compli-
cations, we did note an increase in long-term adverse
outcomes in those women with MFS who underwent
pregnancy. The risk was greatest in those with multiple
pregnancies, those not receiving beta-blocker therapy dur-
ing pregnancy, and those with a larger aortic dimension at
baseline. A larger increase in aortic diameter during preg-
nancy heralded an increase in long-term adverse outcome.
The increase in aortic size during pregnancy is not unique to
women with MFS, but is known to occur during normal
healthy pregnancies (17) and with increased magnitude in
women with pre-eclampsia (17). In contrast to the woman
without MFS wherein increases in aortic diameter of up to
1 mm have been reported (17), our patients had greater
aortic diameters at baseline with up to a 7-mm increase in
aortic root size during pregnancy.
Long-Term Cardiovascular OutcomesTable 2 Long-Term Cardiovascular Outcomes
Variable Pregnant (n  69) Nulliparous (n  29) p Value
Elective surgery 13.0% (9) 6.5% (2) 0.03
Adverse outcome 23.0% (16) 0% (0) 0.002
Values are % (n).
Factors Associated WithLong-Term Adverse CardiovascularOutc me in Wom n it a Prior Pregnancy
Table 3
Fac ors Associ ted With
Long-Term Adverse Cardiovascular
Outcome in Women With a Prior Pregnancy
Variable Odds Ratio 95% Confidence Interval
Aortic size 1.3 1.11–1.61
Number of pregnancies 1.5 1.15–1.97
Prospective care 0.1 0.05–0.39
Medications 0.3 0.14–0.92Aorta 4 cm 3.8 1.11–13.3Despite the lack of data supporting the often quoted
“10% incidence of aortic dissection during pregnancy if the
aorta is 4 cm” (6), and documentation of distal aortic
dissection in pregnant women with MFS following aortic
root replacement (18,19), the 2010 thoracic aortic guidelines
advocate avoidance of pregnancy if the aortic root is 4.0 cm
and recommend surgical ascending aortic replacement in those
who desire pregnancy (10). These recommendations are on
the one hand more stringent, and on the other more liberal,
than the European (20) and Canadian (21) guidelines,
which report an aortic diameter of 45 mm to be consid-
ered safe for pregnancy, and make specific mention of the
ongoing risk of aortic dissection in the pregnant patient
following aortic root replacement. In the 2 prospective
studies to date (15,16), the only women to experience aortic
dissection during pregnancy were 2 who had prior aortic
root replacement. At present there is no data to support a
recommendation for early prophylactic surgery solely for the
purposes of child-bearing. In addition, the feasibility of
monitoring for distal disease in the pregnant women fol-
lowing ascending aortic replacement, is fraught with diffi-
culty. Routine computed tomography angiography is con-
traindicated, and serial routine magnetic resonance imaging
during pregnancy is both costly and difficult for the preg-
nant woman.
The current literature assessing aortic growth rate during
pregnancy in women with MFS is limited to 10 women
noting no difference in aortic growth rate immediately prior
to, or following pregnancy (16). In contrast, our data
demonstrate a consistent increase in aortic growth rate
during pregnancy in women with MFS. In contrast to the
prior studies, our patient cohort had serial echocardio-
graphic monitoring throughout pregnancy, experienced a
greater number of pregnancies per woman, and were fol-
lowed over a longer period of time. Despite this, however,
patient numbers were limited and thus the statistical model
used may be limited to overfitting.
In light of the data presented herein, we counsel our
patients with MFS with regard to both the short-term and
long-term risks of pregnancy. Women are advised that their
aorta will most likely increase in size during pregnancy and
is not likely to return to baseline size. Subsequent pregnan-
cies will further the degree of aortic dilation. Given that the
larger aorta dilates at a more rapid rate, women can
anticipate a higher likelihood of experiencing an adverse
cardiovascular outcome in the long term. The risk of death
or acute ascending aortic dissection during pregnancy or the
Independent Correlates ofLong-Term Adve se CardiovascularOutcome i W m n With a Prior Pregnancy
Table 4
Indep ndent Correlates of
Long-Term Adverse Cardiovascular
Outcome in Women With a Prior Pregnancy
Variable Odds Ratio
95% Confidence
Interval
Initial aortic size 1.8 1.07–3.07
Rate of aortic change (log) 7.4 1.32–41.22postpartum period is extremely low in women who have not
11
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whom the aortic diameter is 45 mm. Careful monitoring
and multidisciplinary management during pregnancy is
beneficial.
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